SCHEDULE: Vanguard Group Reports Zero Beneficial Ownership in West Pharma

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in West Pharmaceutical Services Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 16 to Schedule 13G for West Pharmaceutical Services Inc. Common Stock.
• The filing reports 0% beneficial ownership of West Pharmaceutical Services Inc. Common Stock by The Vanguard Group.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over the securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral for West Pharmaceutical Services Inc. as it primarily reflects an internal organizational change at The Vanguard Group rather than a change in investment strategy or performance.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding West Pharmaceutical Services Inc.'s operations or financial performance.

Management Comments

• The securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of West Pharmaceutical Services Inc.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors. This particular amendment reflects an internal organizational change at The Vanguard Group, a common occurrence for large asset managers, rather than a change in investment thesis regarding West Pharmaceutical Services Inc. It clarifies the reporting structure for beneficial ownership by a major institutional investor.

Stakeholder Impact

• Shareholders of West Pharmaceutical Services Inc.: Minimal direct impact, as the change reflects a reporting structure adjustment by a major institutional investor, not a divestment based on company performance.
• The Vanguard Group investors: May see disaggregated reporting from Vanguard's subsidiaries for West Pharmaceutical Services Inc. shares.

Next Steps

• Certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately in reliance on SEC Release No. 34-39538.

Key Dates

Keywords

West Pharmaceutical Services Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Ownership Change, Internal Realignment